Apposite Capital LLP has obtained CrestOptics

CrestOptics produces advanced microscopy equipment which can be used alongside other imaging devices to improve identification and performance for life science research.

Apposite Capital, a private equity investor in the healthcare industry, now holds over 50% of the shares for CrestOptics S.p.A. The acquisition means that CrestOptics will be regarded as an exciting potential employer and business partner in the industry, with financial backing improving innovation and the process of taking products to market. It will also help in working towards the company’s aim of global growth.

Apposite Healthcare III is a new fund of which CrestOptics is the fourth investment. The purpose of the acquisitions is to speed up growth rate both internally and externally while supporting each business in terms of their funding, workforce, and decision- making.

Dr David Martyr will become the Chair of the Board of Directors at CrestOptics, with the objective to encourage and facilitate accelerated growth.

Chief Executive Officer for CrestOptics, Renato Giacobbo Scavo, said “This agreement demonstrates that CrestOptics is an established brand and a strong player in the worldwide microscopy market. Strategic collaborations with external partners such as Apposite Capital LLP will help us further enforce our market positioning and strengthen our product portfolio with other innovative technologies. Apposite and CrestOptics share the same vision for the future and see huge potential for growth”

Head of Sales and Marketing at CrestOptics, Alessandra Scarpellini, said “CrestOptics has already started an ambitious process of internationalization and this new partnership will boost our efforts to enable us to reach a wider and more diversified market at the global level.”

Founding Partner of Apposite Capital LLP, David Porter, said “CrestOptics, a leader in the development and manufacture of advanced imaging systems for life science research, is exactly the type of differentiated company Apposite seeks to invest in and we are excited to support rapid growth by accelerating further innovation and product development, and facilitate geographical expansion into new markets by leveraging our industry knowledge and contacts. This partnership will cement CrestOptics’ position as a pioneering and reliable imaging innovator and provider on a global scale.”

Chair of Board of Directors of CrestOptics, Dr David Martyr, said “CrestOptics has already demonstrated that it is a highly capable and innovative group, offering very high performance spinning disc imaging systems at affordable prices. With an exciting pipeline of technology and products in development, including expanded super-resolution capabilities, I am delighted to be joining the CrestOptics team.”